CrossPoint Therapeutics

CrossPoint Therapeutics is a South Korean biotechnology company developing next-generation antibody therapeutics based on its proprietary Stealth-Body Fc-silencing platform. The platform is designed to eliminate Fc-mediated effector functions while preserving antibody half-life, with the goal of reducing off-target toxicity and widening the therapeutic window of antibody-based medicines. The company is applying this technology across multiple modalities, including antibody-drug conjugates, dual-target immuno-oncology antibodies, protein delivery, small-molecule delivery, and gene-delivery concepts. Its disclosed pipeline includes EGFR- and PD-L1-targeted ADC programs and a dual-target CD47/CD40 immunotherapy program, all in discovery to preclinical development. CrossPoint positions itself as both an internal drug developer and a potential licensing or collaboration partner for oncology and other high-unmet-need indications such as autoimmune and metabolic diseases.